1. Ma, Fubin, Yao, Jibin, Niu, Xingdong, Shi, Donghai, Da, Mingxu. 2024. MARK4 promotes the malignant phenotype of gastric cancer through the MAPK/ERK signaling pathway. In Pathology, research and practice, 261, 155471. doi:10.1016/j.prp.2024.155471. https://pubmed.ncbi.nlm.nih.gov/39079384/
2. Sultanakhmetov, Grigorii, Limlingan, Sophia Jobien M, Fukuchi, Aoi, Weitemier, Adam Z, Ando, Kanae. 2024. Mark4 ablation attenuates pathological phenotypes in a mouse model of tauopathy. In Brain communications, 6, fcae136. doi:10.1093/braincomms/fcae136. https://pubmed.ncbi.nlm.nih.gov/38712317/
3. Wu, Yi, Zhang, Jingqi, Wang, Weiyi, Kang, Yang, Fu, Lu. 2024. MARK4 aggravates cardiac dysfunction in mice with STZ-induced diabetic cardiomyopathy by regulating ACSL4-mediated myocardial lipid metabolism. In Scientific reports, 14, 12978. doi:10.1038/s41598-024-64006-7. https://pubmed.ncbi.nlm.nih.gov/38839927/
4. Heidary Arash, Emad, Shiban, Ahmed, Song, Siyuan, Attisano, Liliana. 2017. MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells. In EMBO reports, 18, 420-436. doi:10.15252/embr.201642455. https://pubmed.ncbi.nlm.nih.gov/28183853/